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DM1, treatment with IG is an efﬁcacious and cost-saving option compared with ID, 
because Insulin Glargine is associated with a comparable efﬁcacy and lower total costs 
versus ID allowing savings for up to 17.3% per patient-year.
PDB40
COST-UTILITY OF BIPHASIC INSULIN ASPART COMPARED WITH 
PREMIXED HUMAN INSULIN IN TREATMENT OF TYPE-2 DIABETES 
MELLITUS IN POLAND
Szmurlo D1, Gurda-Duda A1, Rys P1, Rutkowski J1, Skrzekowska-Baran I2, Plisko R1, 
Wladysiuk M1
1HTA Consulting, Krakow, Poland, 2Novo Nordisk, Inc., Warsaw, Mazowieckie, Poland
OBJECTIVES: To evaluate cost-utility of biphasic insulin aspart (BIAsp) compared 
with premixed human insulin (Premix) in type-2 diabetes mellitus. METHODS: A 
cost-utility analysis based on The CORE Diabetes Model was conducted, resulting in 
estimation of total direct costs incurred by the National Health Fund and patients, 
life years gained (LYG) and quality-adjusted life years (QALY). The CORE Diabetes 
Model is a complex tool allowing for evaluation of long term health and economic 
outcomes of different treatment options in diabetes mellitus. It is designed as a Markov 
model using Monte Carlo simulations and is based on a series of interconnected sub-
models representing diabetes complications. Cohort baseline characteristics and base-
line distribution between states in the model were derived from published literature. 
Treatments were deﬁned in the means of a change in HbA1c level and hypoglycaemia 
rates calculated on the base of systematic review of RCTs. Default settings were used 
regarding to transition probabilities and utilities of health states. Costs from the 
NHFpatient perspective were calculated. Time horizon in the model was set to 30 
years or until death. In order to estimate the probability of BIAsp being cost effective 
in Polish setting (threshold about 91,000 PLN) bootstrap simulations were performed. 
RESULTS: Both treatments were comparable in terms of LYG (7.47 for BIAsp and 
7.46 for Premix), but BIAsp yielded higher QALY (5.06 vs. 4.95 for BHI). Costs gener-
ated by BIAsp were 30,079 PLN and by premixed insulin 24,970 PLN. Incremental 
cost per QALY for BIAsp compared with Premixed was 49,425 PLN. Probability of 
BIAsp cost effectiveness over Premixed was 63% for QALY and 41% for LYG. 
CONCLUSIONS: Biphasic insulin aspart improves quality of life what translates to 
higher QALY. Despite higher costs associated with treatment, biphasic insulin aspart 
seems to be cost-effective in Polish setting.
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OBJECTIVES: To evaluate cost-utility of insulin glargine (IGlar) in combination 
therapy with oral antidiabetic drugs (OAD) compared with premix insulin (IMix) 
added to OAD and IMix alone in patients with type 2 diabetes. METHODS: A micro-
simulation DES model was used to estimate utilities and costs. Costs were calculated 
from the National Health Fund (NHF) perspective and form NHF plus patient per-
spective. Simulation was executed in one year cycles and terminated at the time of the 
patient’s death. Transition probabilities between health states were calculated based 
on a systematic review of RCTs and supplemented with published literature if neces-
sary. Health states utilities were taken from published literature. Probabilistic sensitiv-
ity analysis was performed to estimate the probability that IGlar with OAD is cost 
effective in Polish settings (threshold about 91,000 PLN). RESULTS: From NHF per-
spective IGlar added to OADs compared with IMix added to OADs was dominant 
therapy e.g less costly (cost difference PLN2,496) and more effective (QALY difference 
0.19) and from NHF plus patient perspective incremental costs were PLN34,662 per 
QALY gained. When compared with insulin mixtures alone, IGlar added to OADs 
was dominant therapy from NHF perspective e.g less costly (cost difference 
PLN1,1105) and more effective (QALY difference 0.13) and from NHF plus patient 
perspective incremental costs were PLN19,800 per QALY gained. From NHF perspec-
tive the probability of IGlarOAD cost effectiveness over IMixOAD was 96.9%,and 
IGlarOAD over IMix alone was 95.7%. From NHF plus patient perspective the 
probability of IGlar cost effectiveness over IMix with OAD was 86.7% and IGlarOAD 
over IMix alone was 82.8%. CONCLUSIONS: According to this analysis performed 
in Poland, Insulin glargine, when added to OADs, seems to be more cost effective then 
insulin mixture, both in combination with OADs and alone.
DIABETES/ENDOCRINE DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: Type 2 diabetes is a difﬁcult disease to manage and treatment is often 
suboptimal for many patients, in particular with insulin therapy. Preﬁlled insulin pens 
provide patients with an easier-to-manage regimen that might lead to improved adher-
ence compared to vial/syringe use. This study analyzed the impact of switching from 
analog insulin in vials to the preﬁlled pen, FlexPen®. METHODS: Real world data 
from a large commercial health plan in the US were investigated and insulin daily 
average consumption (DACON), hypoglycemic events and health care costs were 
analyzed before and after switch to FlexPen®. To control for the general change in 
insulin consumption the FlexPen® cohort was compared to a matched cohort that 
continued analog insulin in vials. RESULTS: A total of 532 patients switched to 
FlexPen® were matched to a cohort continuing on an analog insulin (n  532) admin-
istered by vial/syringe. Insulin DACON increased in both cohorts by 6–10% from the 
12-month pre-period to the 12-month post-period. However, DACON increased 
approximately 2 units more among patients switching to FlexPen® than the vial/
syringe cohort (p  0.0299). In addition, hypoglycemic event rates decreased in the 
FlexPen® cohort from 6.39% in the pre-period to 4.89% in the post-period while 
hypoglycemic events increased in the vial/syringe cohort from 4.89% to 5.83%. 
Despite higher acquisition costs of FlexPen® vs. vials there were no differences in 
pharmaceutical costs (5,414 vs. 4,790; p  0.08) or total costs (13,214 vs. 13,211; p 
 0.95) in the follow-up period. CONCLUSIONS: Patients switched to FlexPen® 
administration experienced an increase in DACON compared to the analog vial 
cohort, which is likely to be associated with improved adherence. Despite increase in 
DACON with FlexPen®, total health care and pharmaceutical costs were similar 
between groups in the follow-up period. Hypoglycemic events decreased in the 
FlexPen® cohort while they increased in the analog vial cohort.
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OBJECTIVES: Few studies have examined the association between medication adher-
ence and age in low income elderly type 2 diabetes patients. The study objective was 
to determine the age associated medication adherence among low-income type-2 dia-
betes patients enrolled in Medicaid. METHODS: This was a retrospective cohort 
study, which compared medication adherence among different age groups of Medicaid 
insured patients with type-2 diabetes newly starting oral antidiabetic medication. The 
study compared the differences in medication adherence among 681 patients aged 
18–44 years, 2327 patients aged 45–64 years and 161 patients aged 65 years newly 
starting antidiabetic medication between July 2001 and June 2002. Medication adher-
ence was measured as medication possession ratio using prescription reﬁll patterns. 
Multiple regression analyses were used to determine the difference in adherence rates 
after adjusting for different covariates. RESULTS: Medication adherence rate was 
signiﬁcantly higher for age group 65 years [0.59 0.31), (p  0.05)] as compared to 
age groups 18–44 years [0.56 (0.31), (p  0.05)] and 44–64 years [0.22 (0.17), (p  
0.05)] respectively. Multiple regression analyses showed that compared to age group 
18–44 years, age groups 65 and 44–64 years had signiﬁcantly higher adherence rate 
by 13.4% and 12.5% respectively. Metformin users were associated with a 34.5% 
decrease in adherence rate as compared to the sulfonylurea users (p  0.05). CON-
CLUSIONS: Better oral antidiabetic medication adherence was associated with 
increased age. Future research should investigate patient-related factors affecting medi-
cation adherence with an emphasis on the development of efﬁcient medication man-
agement therapies which may in turn, reduce health care costs and disease burden in 
low-income elderly diabetic patients.
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OBJECTIVES: To examine the relationship between Hemoglobin A1c (HbA1c) values 
and medication adherence over time in diabetic patients participating in a pharmacist-
conducted Medication Therapy Management program (MTMP). METHODS: This 
study used a prospective, intention-to-treat, pre-post longitudinal design assessing the 
impact of a pharmacist-conducted employer sponsored MTMP on clinical and human-
istic outcomes of employees, their spouses and covered dependents with Type 2 dia-
betes. Enrollment began in January 2008. As an incentive to participate, patients 
received a 3 month supply of medications at the cost of one copay. Pharmacist inter-
ventions included medication therapy reviews, discussing details about patients’ 
disease state and the importance of medication adherence, and informing patients 
about appropriate lifestyle modiﬁcations. HbA1c was measured using the Cholestech 
LDX at the pharmacy every three months and adherence was measured at baseline, 
3 months, and nine months. Patient reported adherence was measured using the 
Morisky scale. Currently, most patients have completed six months in the program 
therefore analysis focused on comparing baseline and the three month time point. A 
Wilcoxon signed-rank test was used to determine changes in HbA1c values over time 
and a Spearman correlation was used to examine any relationship. RESULTS: Patients 
who began the program with uncontrolled HbA1c values experienced a signiﬁcant 
decrease of 0.79% in HbA1c values from baseline to 3 months. Adherence levels 
improved signiﬁcantly from baseline to 3 months (p  0.05). There was a signiﬁcant 
inverse relationship between A1c levels and medication adherence at 3 months (Spear-
man’s R  0.264, A  0.05, N  70). Final results will be presented at the conference. 
CONCLUSIONS: As adherence to medications increased there was a decrease in 
HbA1c values. Patients with improved adherence were able to maintain better 
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glycemic control. To further improve outcomes for employees with diabetes and 
improve long-term cost-savings, employers might need to focus on programs that 
target medication adherence.
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OBJECTIVES: To elicit utility values associated with type 2 diabetes from Korean 
and Taiwanese populations and identify key drivers of preferences within these popu-
lations. Utility studies conducted in non-Asian populations often elicit preferences 
using a survey population or scaling method that is not preferred by Asian payers. As 
the use of pharmacoeconomics becomes more prevalent in Asia there is a greater need 
to understand implications of adapting overseas studies and to identify appropriate 
utility values when calculating cost utility ratios in the region. METHODS: A total 
of 132 study participants (67 from the general population and 65 type 2 diabetes 
patients) were recruited equally from Korea and Taiwan. Health states for type 2 
diabetic patients were adapted from a published UK study. Utilities for the health 
states were elicited using a chained standard gamble method (SG) and the EQ-5D. A 
paper SG was administered with multiple researchers assisting and verifying respon-
dents’ logic. Demographic data were collected. Analyses were conducted using 
approved methods and compared to published UK utility values. RESULTS: The mean 
utility of type 2 diabetes patients without complications was 0.937 (EQ-5D among 
patients). Asian patients indicated greater disutility from weight gain (0.0488 for 5% 
gain) and less utility from weight loss (0.0184 for 5% loss), which was similar to 
ﬁndings from the UK. The average disutility associated with gastrointestinal side 
effects was 0.07. CONCLUSIONS: Localized utility studies provide insight into the 
geographical preferences related to type 2 diabetes health states. The value placed 
upon weight loss versus weight gain, a respondent’s baseline BMI and differences in 
study design may drive variation in utilities between Asia and the UK. The ability to 
adapt utility studies conducted overseas to capture Asian preferences using methods 
preferred by Asian payers has meaningful implications for future cost utility studies 
conducted in Asia.
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OBJECTIVES: Recent advances in monoclonal antibody therapies offer the prospect 
of the prevention or amelioration of type 1 diabetes (T1DM). The present study was 
designed to capture UK preference weights for outcomes of infusion therapy for chil-
dren (8–12yrs); adolescents (13–17yrs) and adults. Such values could be used in a cost 
effectiveness analysis. METHODS: In-depth interviews were conducted with adults 
(n  4) and parents of children (n  4) and parents of adolescents (n  4) all with 
T1DM to characterise their quality of life. These data, plus an interview with a clinical 
expert and ﬁndings from a literature review were used to construct vignette descrip-
tions of health. Vignettes described T1DM; T1DM with reduced need for insulin; 
T1DM insulin free; receiving infusion therapy and receiving infusion therapy plus 
acute phase reaction(APR). Separate vignettes described adults, adolescents and chil-
dren. Following expert review of content validity, vignettes were rated (using the 
standard gamble interview) by the general public, adults with T1DM and parents of 
children with T1DM. Participants also the EQ-5D, PedsQL, and Hyperglycemic Fear 
Survey (data will be reported). Mixed model analyses were used to estimate the inﬂu-
ence on utility of different participant characteristics. RESULTS: Each health state 
was a signiﬁcant predictor of utility. The general public gave signiﬁcantly different 
utilities to the T1DM participants (p  .02). The utility gain associated with successful 
treatment was greater for the public versus T1DM group (reduced insulin 0.026 vs 
0.021, insulin-free 0.073 vs 0.057) and the disutility greater for undergoing infu-
sion therapy (on-infusion 0.114 vs 0.093, on-infusion with APR 0.159 vs 0.131). 
CONCLUSIONS: The general public and people with diabetes (or parents of children) 
all place signiﬁcant value on reducing the need for insulin injections, whilst recognising 
the disutility of undergoing infusion-based therapies. The differences between these 
groups may reﬂect adjustment and coping.
PDB47
HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH TYPE 2 
DIABETES OVER THE 24 MONTHS FOLLOWING INITIATION OF 
INSULIN
Meadows K1, Smith HT2, Nicolay C3
1North East London Consortium for Research and Development (NELCRAD), London, UK, 
2Eli Lilly and Company, Surrey, UK, 3Eli Lilly and Company, Bad Homburg, Germany
OBJECTIVES: To investigate health related quality of life (HRQL) using EuroQol 
EQ-5D in patients with type 2 diabetes over the 24 months following insulin initiation. 
METHODS: INSTIGATE is a European prospective observational study investigating 
patients with type 2 diabetes initiating insulin during usual care. Follow-up data on 
resource use, treatment, clinical and patient reported outcomes over the 24 months 
following insulin initation were collected in Germany, Greece and Spain (N  564). 
RESULTS: Mean (SD) HbA1c was 9.4(1.72)% at insulin initiation, 7.2(1.03)% after 
6 months, and 7.2(1.07)% after 24 months. Only in Germany did mean HbA1c fall 
below 7%. Treatment approach varied; at baseline in Germany patients were pre-
scribed more intensive insulin regimens (mean 3.1 injections/day). In Greece and Spain 
most patients were prescribed either basal-only or premix-only with fewer mean daily 
injections (1.8 and 1.4 respectively). Across all patients at baseline, 14.5% reported 
problems with the EQ-5D self-care dimension, 37.9% reported problems with mobil-
ity and 31.4% with usual activities. In Greece, 68% of patients reported problems 
with anxiety/depression (overall: 54.1%); in Germany, 63% reported problems with 
pain/discomfort (overall: 52.3%). In the ﬁve dimensions, 62.4–80.3% of patients 
reported no change between baseline and 24 months, 10.4–16.1% reported worsening 
problems, and 8.6–22.9% reported improvement. Mean(SD) baseline EQ-5D visual 
analogue scale scores (VAS) were: Germany 65.7(19.07), Greece 64.8(19.24), Spain 
63(18.32). Patients in Greece saw the greatest and most sustained improvement in 
VAS; mean increase from baseline to 6 months 13.9(15.08) and baseline to 24 months 
11.9(17.82). In Germany and Spain increases from baseline to 6 months were 
12.4(16.5) and 4.6(17.69) respectively. From baseline to 24 months there was an 
increase of only 6.1(18.86) in Germany and 6.7(20.83) in Spain. CONCLUSIONS: 
Following insulin initiation there was an increase in HRQL (VAS) through 6 months, 
although this appeared to diminish between 6 and 24 months.
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OBJECTIVES: To explore the concept of the Minimum Clinically Important Difference 
(MID) of the Worry Scale of the Hypoglycaemia Fear Survey (HFS-II) and to quantify    
the clinical importance of different types of patient-reported hypoglycaemia. 
METHODS: An observational study was conducted in Germany with 392 patients 
with type 2 diabetes mellitus treated with combinations of oral anti-hyperglycaemic      
agents. Patients completed the HFS-II, the Treatment Satisfaction Questionnaire 
for Medication (TSQM), and reported on severity of hypoglycaemia. Distribution- 
and anchor-based methods were used to determine MID. In turn, MID was used to 
determine if hypoglycaemia with or without need for assistance was clinically meaning-
ful compared to having had no hypoglycaemia. RESULTS: 112 patients (28.6%) 
reported hypoglycaemic episodes, with 15 patients (3.8%) reporting episodes that 
required assistance from others. Distribution- and anchor-based methods resulted 
in MID between 2.1 and 5.8 and 3.6 and 3.9 for the HFS-II, respectively. Patients 
who reported hypoglycaemia with (21.6, 95% conﬁdence interval (CI) 15.1; 28.1)        
and without (12.1, 95% CI 9.7; 14.5) need for assistance scored higher on the    
HFS-II (range 0 to 72) than patients who did not report hypoglycaemia (6.0, 95% CI 
5.0; 7.0). CONCLUSIONS: We provide MID for HFS-II. Our ﬁndings indicate 
that the differences between having reported no hypoglycaemia, hypoglycaemia 
without need for assistance, and hypoglycaemia with need for assistance appear to be 
clinically important in patients with type 2 diabetes mellitus treated with oral anti-   
hyperglycaemic agents.
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OBJECTIVES: Adult Growth Hormone Deﬁciency (AGHD) is a poorly understood 
disease. As a result, treatment patterns and health care access vary by country and 
misunderstandings regarding the patient reported impacts are common. A well devel-
oped PRO measure identifying disease and treatment issues for this population and 
sensitive to treatment effects is critical for future research and clinical decision making. 
The purpose of the study was to understand the full spectrum of PRO issues in AGHD 
and develop a validation ready measure of these impacts. METHODS: As the ﬁrst 
phase of the PRO measure development process, qualitative data was collected from 
the literature, experts and patients and transcripts thematically coded according to 
grounded theory. Based on a synthesis of all information, a conceptual model of the 
impact of disease and treatment was developed and a PRO measure generated. 
RESULTS: 39 AGHD patients (7 focus groups, 3 telephone interviews) and 6 clinical 
experts in three countries (US, UK, Germany) were interviewed regarding the impact 
of AGHD and treatment on functioning, well-being and treatment burden. The mean 
age of patients was 50.7(range 23–82), mean age at diagnosis of 39.7 (range 4–71) 
and 87% were currently on treatment. Across countries common impacts were identi-
ﬁed in the domains of Energy, Physical Health, Psychological Health, Cognition and 
Treatment Burden. A conceptual model of the impacts of AGHD, their consequences 
and modiﬁers to the relationship was developed and a 46 item PRO impact measure 
(TRIM-AGHD) was generated with 5 discrete domains. The TRIM-AGHD was then 
cognitively debriefed in 9 patients and a validation ready version created. CONCLU-
SIONS: The instrument development process, the full conceptual model, and discus-
sion of clinical implications will be presented. This information should help clinicians 
identify key PRO issues for AGHD, facilitate targeted treatments and allow for 
meaningful measurement of treatment effect.
